Drugs / AP303
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06666283 | Feb → Sep 2025 overdue | diabetic kidney disease | Alebund Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06308523 | Mar → May 2024 | — | Alebund Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05503693 | Dec 2022 → Jul 2023 | — | Alebund Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05503693 ↗ |
| Route | Oral | “orally administered AP303 will be assessed” NCT05503693 ↗ |